SCHEMBL5156776

SCHEMBL5156776

CCCCOC(=O)N1CC(C(=O)O)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
S1PR1 P21453 8/20 0.46
S1PR5 Q9H228 8/20 0.46
S1PR3 Q99500 6/20 0.45
ALDH1A1 P00352 2/20 0.42
GBA2 Q9HCG7 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
ATM Q13315 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
S1PR4 O95977 1/20 0.39
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2345851 0.87 SMN1; SMN2 (0.51) LMNAPOLBSMN1; SMN2S1PR1S1PR5
SCHEMBL14159621 0.87 SMN1; SMN2 (0.51) LMNAPOLBSMN1; SMN2S1PR1S1PR5
SCHEMBL28253726 0.87 SMN1; SMN2 (0.51) LMNAPOLBSMN1; SMN2S1PR1S1PR5
SCHEMBL25326449 0.86 LMNA (0.53) LMNAPOLBSMN1; SMN2ALDH1A1GBA2
SCHEMBL5158334 0.86 LMNA (0.53) LMNAPOLBSMN1; SMN2ALDH1A1GBA2
SCHEMBL2357857 0.85 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2S1PR5ALDH1A1
SCHEMBL5495665 0.85 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2S1PR5ALDH1A1
SCHEMBL8303596 0.85 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2S1PR5ALDH1A1
SCHEMBL30816157 0.84 LMNA (0.54) LMNAPOLBSMN1; SMN2ALDH1A1GBA2
SCHEMBL27151384 0.84 LMNA (0.54) LMNAPOLBSMN1; SMN2ALDH1A1GBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4326714-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-02-28 EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 WO disclosed
WO-2023067354-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 EP disclosed
WO-2019032743-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-02-14 WO disclosed
EP-3201196-A1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES UCB Biopharma SPRL (BE) 2017-08-09 EP disclosed
WO-2016050975-A1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2016-04-07 WO disclosed
EP-1747222-A1 PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR Proskelia SAS (FR) 2007-01-31 EP disclosed
WO-2005123734-A1 PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR PROSKELIA SAS (FR) 2005-12-29 WO disclosed
EP-1089964-A1 HYDRAZINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2001-04-11 EP disclosed
WO-2000000465-A1 HYDRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-01-06 WO disclosed
EP-0874809-A1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1998-11-04 EP disclosed
WO-1997025309-A1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1997-07-17 WO disclosed